Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.22.1
Stock-Based Compensation
9 Months Ended
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 7. Stock-Based Compensation

 

In June 2020, the Board of Directors adopted the 2020 Stock Incentive Plan, which provided for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company’s employees, officers, directors, advisors, and outside consultants for the purchase of up to 1,650,000 shares of the Company’s common stock. On October 22, 2021, the Company’s stockholders approved an increase of the total authorized shares to 3,650,000 shares. Other awards include restricted stock, restricted stock units, stock appreciation rights and other stock-based awards. Other stock-based awards are awards valued in whole or in part by reference to, or are otherwise based on, shares of common stock. Stock options generally vest over a four-year period, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). The awards expire in five years from the date of grant. As of March 31, 2022, the Company had  1,183,667 shares available for future issuance under the 2020 Stock Incentive Plan.

 

Stock Options

 

The Company grants non-qualified stock option awards under the 2020 Stock Incentive Plan to its Board of Directors, employees and consultants of the Company. These awards are subject to the satisfaction of certain performance targets and vesting requirements pursuant to the award.

 

The Company estimates the fair value of stock-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables, such as assumptions we make for the volatility of our common stock the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term, and our expected dividend yield. Each of these inputs is subjective and generally requires significant judgement to determine. Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the respective award.

 

The following table summarizes the range of key assumptions used to determine the fair value of stock options granted during the three and nine months ended March 31, 2022 and 2021.

 

 

    Three Months Ended
March 31,
    Nine Months Ended
March 31,
 
    2022     2021     2022     2021  
Risk-free interest rate     1.29% – 2.14 %     0.27% – 0.64 %     0.79% – 2.14 %     0.27% – 0.64 %
Expected term (in years)     4.50       2.83.54       3.04.50       2.8 3.54  
Expected volatility     50.0 %     49.6 %     50.0 %     49.6 %
Expected dividend yield                

  

The following table summarizes stock option activity for the nine months ended March 31, 2022:

 

   

Number

of

Shares

   

Weighted

Average Exercise

Price

   

Weighted

Average

Remaining

Contractual

Term

(Years)

   

Aggregate

Intrinsic

Value

 
                         
Outstanding at June 30, 2021     604,404     $ 2.18       4.7     $ 2,802,420  
Granted     879,429     $ 6.16                  
Exercised     -     $ -                  
Forfeited     -     $ -                  
Outstanding at March 31, 2022     1,483,833     $ 4.54       4.5     $ 3,765,907  
Options exercisable at March 31, 2022     225,741     $ 2.54       4.0     $ 1,025,177  

 

The weighted-average grant date fair value of options awarded during the nine months ended March 31, 2022 was approximately $3.07 per share. As of March 31, 2022, unrecognized stock-based compensation expense related to unvested stock options totaled approximately $2,820,786 which is expected to be recognized over a weighted average period of 3.1 years.

 

 

Restricted Stock

 

In September 2020, the Company awarded 982,500 shares of restricted common stock to its former CEO, at a grant date fair value of $0.11 per share. The restrictions are subject to the satisfaction of certain performance targets and vesting requirements pursuant to the award and employment agreement.

 

Upon the IPO in May 2021, the former CEO became entitled to the full vesting of his restricted stock.

 

Compensation Expense

 

The Company recorded stock-based compensation expenses for the following periods:

 

    2022     2021     2022     2021  
    Three Months Ended     Nine Months Ended  
    March 31,     March 31,  
    2022     2021     2022     2021  
Research and development   $ 245     $ 2,105     $ 12,233     $ 2,105  
General and administrative     125,009       45,302       241,476       82,404  
Total stock-based compensation expense   $ 125,254     $ 47,407     $ 253,709     $ 84,509